Patient Site Healthcare Professional Site
VIVITROL (naltrexone for extended-release injectable suspension) VIVITROL: A Treatment Option For The Daily Struggle Against Alcohol Dependence. One dose all month long.
Healthcare Professional Site
Prescribing Information
Send to a Friend
Homepage About Vivitrol Request Information SEARCH
About VIVITROL
My Path to Recovery
Overview


Mechanism of action


Efficacy


Dosage/Administration


Adherence


Safety Considerations


VIVITROL Preparation and Administration
What is VIP3?


How do I start a patient on therapy?

Dosage/Administration

VIVITROL 380 mg

  • VIVITROL must be administered by a healthcare professional.
  • Administer once a month or every 4 weeks as a gluteal IM injection, alternating buttocks with each injection
  • Do not administer intravenously
  • If a patient misses a dose, instruct the patient to receive the next dose as soon as possible
  • Pretreatment with oral naltrexone is not required before using VIVITROL

How to prepare and administer VIVITROL

Our instructional video addresses proper dose preparation, administration, and safe disposal of needles and vials. Click here to view the instructional video.

More about VIVITROL administration

The injection must be administered using the safety needle supplied and the carton components provided (see below).

VIVITROL (naltrexone for extended-release injectible suspension) is supplied in single-use cartons. Each carton contains the items shown below.7

Carton contents

For more information about VIVITROL administration, please read the complete Prescribing Information including boxed warning for VIVITROL.
Important Safety Information
Naltrexone has the capacity to cause hepatocellular injury when given in excessive doses. Naltrexone is contraindicated in acute hepatitis or liver failure, and its use in patients with active liver disease must be carefully considered in light of its hepatotoxic effects. The margin of separation between the apparently safe dose of naltrexone and the dose causing hepatic injury appears to be only five-fold or less. VIVITROL does not appear to be a hepatotoxin at the recommended doses. Patients should be warned of the risk of hepatic injury and advised to seek medical attention if they experience symptoms of acute hepatitis. Use of VIVITROL should be discontinued in the event of symptoms and/or signs of acute hepatitis.
VIVITROL is indicated for the treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to initiation of treatment with VIVITROL.

Patients should not be actively drinking at the time of initial VIVITROL administration.

Treatment with VIVITROL should be part of a comprehensive management program that includes psychosocial support.